Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide

Cationic antimicrobial peptides (CAPs) exhibit promising anticancer activities. In the present study, we have examined the in vivo antitumoral effects of a 9-mer peptide, LTX-302, which is derived from the CAP bovine lactoferricin (LfcinB). A20 B cell lymphomas of BALB/c origin were established by subcutaneous inoculation in syngeneic mice. Intratumoral LTX-302 injection resulted in tumor necrosis and infiltration of inflammatory cells followed by complete regression of the tumors in the majority of the animals. This effect was T cell dependent, since the intervention was inefficient in nude mice. Successfully treated mice were protected against rechallenge with A20 cells, but not against Meth A sarcoma cells. Tumor resistance could be adoptively transferred with spleen cells from LTX-302-treated mice. Resistance was abrogated by depletion of T lymphocytes, or either the CD4+ or CD8+ T cell subsets. Taken together, these data suggest that LTX-302 treatment induced long-term, specific cellular immunity against the A20 lymphoma and that both CD4+ and CD8+ T cells were required. Thus, intratumoral administration of lytic peptide might, in addition to providing local tumor control, confer a novel strategy for therapeutic vaccination against cancer.

[1]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[2]  F. Sharom,et al.  Interaction of the P-glycoprotein Multidrug Transporter with Peptides and Ionophores (*) , 1995, The Journal of Biological Chemistry.

[3]  Y. Bang,et al.  In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines , 2003, Peptides.

[4]  David M. Conrad,et al.  Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines , 2005, Molecular Cancer Therapeutics.

[5]  D. Hoskin,et al.  Cationic antimicrobial peptides as novel cytotoxic agents for cancer treatment , 2006, Expert opinion on investigational drugs.

[6]  W. Yoon,et al.  Effect of O-glycosylated mucin on invasion and metastasis of HM7 human colon cancer cells. , 1996, Biochemical and biophysical research communications.

[7]  Y. Yoo,et al.  Bovine Lactoferrin and Lactoferricin, a Peptide Derived from Bovine Lactoferrin, Inhibit Tumor Metastasis in Mice , 1997, Japanese journal of cancer research : Gann.

[8]  O. Seternes,et al.  Macrophage cytotoxicity against murine meth A sarcoma involves nitric oxide-mediated apoptosis. , 1996, Biochemical and biophysical research communications.

[9]  Carl G. Figdor,et al.  In Situ Tumor Ablation Creates an Antigen Source for the Generation of Antitumor Immunity , 2004, Cancer Research.

[10]  D H Sachs,et al.  Establishment and characterization of BALB/c lymphoma lines with B cell properties. , 1979, Journal of immunology.

[11]  Z. Figaszewski,et al.  Changes in electric charge and phospholipids composition in human colorectal cancer cells , 2005, Molecular and Cellular Biochemistry.

[12]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2010, Nature.

[13]  C. Bucana,et al.  Elevated expression of phosphatidylserine in the outer membrane leaflet of human tumor cells and recognition by activated human blood monocytes. , 1991, Cancer research.

[14]  J. Svendsen,et al.  Antibacterial activity of 15-residue lactoferricin derivatives. , 2000, The journal of peptide research : official journal of the American Peptide Society.

[15]  Kenneth C. Torres,et al.  Specimen Preparation for Scanning Electron Microscopy , 1989 .

[16]  S. Müller,et al.  HMGB1 is an endogenous immune adjuvant released by necrotic cells , 2004, EMBO Reports.

[17]  M. Herlyn,et al.  Experimental local therapy of human melanoma with lytic magainin peptides , 1995, International journal of cancer.

[18]  Y. Chen,et al.  RGD-Tachyplesin inhibits tumor growth. , 2001, Cancer research.

[19]  Nina Bhardwaj,et al.  Consequences of cell death: exposure to necrotic tumor cells , 2000 .

[20]  J. Svendsen,et al.  Enhanced antitumor activity and selectivity of lactoferrin-derived peptides. , 2002, The journal of peptide research : official journal of the American Peptide Society.

[21]  Y. Shai,et al.  Suppression of Human Prostate Tumor Growth in Mice by a Cytolytic d-, l-Amino Acid Peptide , 2004, Cancer Research.

[22]  John J. Bozzola,et al.  Electron microscopy : principles and techniques for biologists , 1992 .

[23]  D. Hoskin,et al.  Studies on anticancer activities of antimicrobial peptides. , 2008, Biochimica et biophysica acta.

[24]  R. Mortara,et al.  Effective topical treatment of subcutaneous murine B16F10-Nex2 melanoma by the antimicrobial peptide gomesin. , 2008, Neoplasia.

[25]  M. Hollingsworth,et al.  Oligosaccharides Expressed on MUC1 Produced by Pancreatic and Colon Tumor Cell Lines* , 1997, The Journal of Biological Chemistry.

[26]  Ø. Rekdal,et al.  Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin‐derived peptide , 2003, Journal of peptide science : an official publication of the European Peptide Society.

[27]  B. Gawrońska,et al.  Membrane Disrupting Lytic Peptide Conjugates Destroy Hormone Dependent and Independent Breast Cancer Cells in vitro and in vivo , 2003, Breast Cancer Research and Treatment.

[28]  Y. Shai,et al.  Host defense peptides as new weapons in cancer treatment , 2005, Cellular and Molecular Life Sciences CMLS.

[29]  K. Gelmon,et al.  In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. , 2000, Anti-cancer drug design.

[30]  P. Srivastava,et al.  Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. , 2000, International immunology.

[31]  Paolo Bernardi,et al.  BMAP-28, an Antibiotic Peptide of Innate Immunity, Induces Cell Death through Opening of the Mitochondrial Permeability Transition Pore , 2002, Molecular and Cellular Biology.

[32]  B. Sveinbjørnsson,et al.  The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo , 2006, International journal of cancer.

[33]  Michael J. Dykstra,et al.  Specimen Preparation for Transmission Electron Microscopy , 1992 .

[34]  J. Svendsen,et al.  The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells , 2004, Journal of peptide science : an official publication of the European Peptide Society.

[35]  J. Mai,et al.  A proapoptotic peptide for the treatment of solid tumors. , 2001, Cancer research.

[36]  Stefania Gallucci,et al.  Natural adjuvants: Endogenous activators of dendritic cells , 1999, Nature Medicine.

[37]  B. Haug,et al.  Enhanced antitumour activity of 15‐residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N‐terminal modifications , 2003, Journal of peptide science : an official publication of the European Peptide Society.

[38]  Erkki Ruoslahti,et al.  Anti-cancer activity of targeted pro-apoptotic peptides , 1999, Nature Medicine.

[39]  Takashi Iwasaki,et al.  Selective cancer cell cytotoxicity of enantiomeric 9-mer peptides derived from beetle defensins depends on negatively charged phosphatidylserine on the cell surface , 2009, Peptides.

[40]  M. Zasloff,et al.  Anticancer efficacy of Magainin2 and analogue peptides. , 1993, Cancer research.

[41]  J. Svendsen,et al.  Evidence for a direct antitumor mechanism of action of bovine lactoferricin. , 2002, Anticancer research.

[42]  Vyacheslav Kalchenko,et al.  Inhibition of tumor growth and elimination of multiple metastases in human prostate and breast xenografts by systemic inoculation of a host defense-like lytic peptide. , 2006, Cancer research.